Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of Atopic Dermatitis for at least 3 months
Investigator's Global Assessment (IGA) Score of 2 or 3
Eczema Area Severity Index (EASI) score of 3-21
Body Surface Area (BSA) of 2-20%
Peak pruritus-Numerical Rating Scale (PPNRS) of Grade 2 or more
You may not be if
Other forms of dermatological diseases (other than atopic dermatitis)
Fitzpatrick skin type score greater than 5
Clinically significant abnormal ECG, vital signs, and laboratory values
Infection with HBV, HCV, herpes zoster or tuberculosis
Clareo Health | Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
